DUBLIN–(BUSINESS WIRE)–The “Isocitrate Dehydrogenase (IDH) inhibitors- Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.
This “Isocitrate Dehydrogenase (IDH) inhibitors – Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Isocitrate Dehydrogenase (IDH) inhibitors pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Isocitrate Dehydrogenase (IDH) inhibitors: Overview
Isocitrate dehydrogenase (IDH) is a key enzyme involved in the conversion of isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid (TCA) cycle. IDH mutation produces a neomorphic enzyme, which can lead to the abnormal accumulation of R-2-HG and promotes leukemogenesis.
IDH mutation occurs in 20% of acute myeloid leukemia (AML) patients, mainly including IDH1 R132, IDH2 R140, and IDH2 R172. Different mutant isoforms have different prognostic values.
Mutations in the enzyme isocitrate dehydrogenase 1 (IDH1) lead to metabolic alterations and a sustained formation of 2-hydroxyglutarate (2-HG). 2-HG is an oncometabolite as it inhibits the activity of α-ketoglutarate-dependent dioxygenases such as ten-eleven translocation (TET) enzymes.
Isocitrate Dehydrogenase (IDH) inhibitors Emerging Drugs Chapters
This segment of the Isocitrate Dehydrogenase (IDH) inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Isocitrate Dehydrogenase (IDH) inhibitors Emerging Drugs
Vorasidenib: Agios Pharmaceuticals
Vorasidenib, an investigational, oral, selective, brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, is currently being evaluated in the registration-enabling Phase 3 INDIGO study as a potential treatment for patients with residual or recurrent Grade 2 non-enhancing glioma.
Isocitrate Dehydrogenase (IDH) inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Isocitrate Dehydrogenase (IDH) inhibitors drugs segregated based on following parameters that define the scope of the report.
Major Players working on Isocitrate Dehydrogenase (IDH) inhibitors
There are approx. 10+ key companies which are developing the Isocitrate Dehydrogenase (IDH) inhibitors. The companies which have their Isocitrate Dehydrogenase (IDH) inhibitors drug candidates in the most advanced stage, i.e. phase III include, Agios Pharmaceuticals.
Phases
This report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Isocitrate Dehydrogenase (IDH) inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Isocitrate Dehydrogenase (IDH) inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Isocitrate Dehydrogenase (IDH) inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Isocitrate Dehydrogenase (IDH) inhibitors drugs.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Isocitrate Dehydrogenase (IDH) inhibitors R&D. The therapies under development are focused on novel approaches for Isocitrate Dehydrogenase (IDH) inhibitors.
May 2020: May 2020, Agios Pharmaceuticals reported updated data from the ongoing Phase 1 study evaluating single agent vorasidenib in isocitrate dehydrogenase (IDH)-mutant advanced solid tumors, including glioma. Data from the non-enhancing glioma population were featured in an oral presentation at the 2020 American Society of Clinical Oncology (ASCO) annual meeting, which is being held virtually.
Isocitrate Dehydrogenase (IDH) inhibitors Report Insights
- Isocitrate Dehydrogenase (IDH) inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Isocitrate Dehydrogenase (IDH) inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Isocitrate Dehydrogenase (IDH) inhibitors drugs?
- How many Isocitrate Dehydrogenase (IDH) inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Isocitrate Dehydrogenase (IDH) inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Isocitrate Dehydrogenase (IDH) inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Isocitrate Dehydrogenase (IDH) inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Bayer
- Agios Pharma
- Daiichi Sankyo
- Ohm Oncology
Key Products
- BAY 1436032
- Vorasidenib
- DS 1001
- OMT 004
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/odnuen
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900